


88 Rec'd PCT/PTO 11 FEB 1997

FORM PTO-1390 (REV. 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER ST94065-US
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, See 37 CFR 1.52) 08/776786
INTERNATIONAL APPLICATION NO. PCT/FR95/01002	INTERNATIONAL FILING DATE 26 July 1995	PRIORITY DATE CLAIMED 12 August 1994	
TITLE OF INVENTION ADENOVIRUS COMPRISING A GENE CODING FOR GLUTATHIONE PEROXIDASE			
APPLICANT(S) FOR DO/EO/US Martine BARKATS, Jacques MALLET and Frédéric REVAH			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)), and Power of Attorney, unsigned. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 			
Items 11. to 16. below concern other document(s) or information included:			
<ol style="list-style-type: none"> <input type="checkbox"/> An information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> Other items or information: 			
CERTIFICATION UNDER 37 CFR 1.10			
GB840710816 US		February 11, 1997	
"Express Mail" Mailing Number		Date of Deposit	
I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231, Attn. EO/US			
Paula L. Dickey (Type or print name of person mailing paper)		Paula L. Dickey (Signature of person mailing paper)	

U.S. APPLICATION NO. (If Known, see C.F.R. 1.5)	INTERNATIONAL APPLICATION NO. PCT/FR95/01002	ATTORNEY'S DOCKET NUMBER ST94065-US
17. [X] The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$ 910.00 International preliminary examination fee paid to USPTO (37 CFR 1.482)\$ 700.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$ 770.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$ 96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =		CALCULATIONS PTO use only
		\$ 910.00
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$
Claims	Number Filed	Number Extra
Total Claims	29 -20 =	9
Independent Claims	2 - 3 =	0
Multiple dependent claim(s) (if applicable)		+ \$260.00
TOTAL OF ABOVE CALCULATIONS =		\$ 1108.00
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement\$ must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).		
SUBTOTAL =		\$ 1108.00
Processing fee of \$130.00 for furnishing the English translation later the [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$
TOTAL NATIONAL FEE =		\$ 1108.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$
TOTAL FEES ENCLOSED =		\$ 1108.00
		Amount to be: refunded \$
		charged \$
a. [] A check in the amount of \$_____ to cover the above fee is enclosed. b. [X] Please charge my Deposit Account No. <u>18-1982</u> in the amount of \$ <u>1108.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>18-1982</u> . A duplicate copy of this sheet is enclosed.		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.		
SEND ALL CORRESPONDENCE TO: Martin F. Savitzky, Esquire Rhone-Poulenc Rorer Inc. Legal-Patents, #3C43 P.O. Box 5093 Collegeville, PA 19426-0997 Telephone: (610) 454-3816 Facsimile: (610) 454-3808		Signature  Martin F. Savitzky Name 29,699 Registration Number Date February 11, 1997

08/776786

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: BARKATS et al. Group Art Unit:
Serial No.: To Be Assigned Examiner:
U.S. National Stage of PCT/FR95/01002
Filed: Concurrently Herewith
For: Adenovirus Comprising A Gene Coding For Glutathione Peroxidase
To: The Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

CERTIFICATE OF MAILING (37 CFR § 1.10)

GB840710816 US February 11, 1997
"Express Mail" Mailing Number Date of Deposit

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231, Attn. EO/US.

Paula L. Dickey
(Type or print name of person mailing paper)

Paula L. Dickey
(Signature of person mailing paper)

PRELIMINARY AMENDMENT

Please enter the following amendment to the English Translation of the International Application before examining this application.

In the Claims

Please cancel claims 1-26 without prejudice.

Please add the following new claims 27-55:

27. A replication defective recombinant adenovirus comprising at least one DNA sequence encoding all or an active part of a glutathione peroxidase, or a derivative thereof.

28. An adenovirus according to claim 27, wherein the DNA sequence is a cDNA sequence.

29. An adenovirus according to claim 27, wherein the DNA sequence is a gDNA sequence.

30. An adenovirus according to claim 27, wherein the DNA sequence encodes a bovine glutathione peroxidase.

31. An adenovirus according to claim 27, wherein the DNA sequence encodes a human glutathione peroxidase.

32. A replication defective recombinant adenovirus comprising at least one DNA sequence encoding an antisense sequence capable of controlling the expression of a gene encoding glutathione peroxidase.

33. An adenovirus according to claim 32, wherein the antisense sequence is an antisense RNA capable of controlling the translation of the mRNA for a glutathione peroxidase.

34. An adenovirus according to claim 27, wherein the DNA sequence is under the control of signals controlling expression in target cells.

35. An adenovirus according to claim 34, wherein the signal is a viral promoter.

36. An adenovirus according to claim 35, wherein the promoter is selected from the group consisting of E1A, MLP, CMV and RSV-LTR promoters.

37. An adenovirus according to claim 27, comprising a gDNA or cDNA sequence encoding a bovine glutathione peroxidase under the control of an RSV-LTR promoter.

38. An adenovirus according to claim 27, comprising a gDNA or cDNA sequence encoding a human glutathione peroxidase under the control of an RSV-LTR promoter.

39. An adenovirus according to claim 27, lacking regions of the genome necessary for its replication in a target cell.

40. An adenovirus according to claim 39, comprising ITRs and a sequence permitting encapsidation, wherein the E1 gene and at least one of the E2, E4, or L1-L5 genes are not functional.

41. An adenovirus according to claim 39, wherein said adenovirus is an Ad 2 or Ad 5 human adenovirus or a CAV-2 canine adenovirus.

42. A method for the treatment and/or prevention of a neurodegenerative disease comprising administering to a patient an adenovirus according to claim 27.

43. A method according to claim 42, wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, ALS, trisomy 21, atherosclerosis, cardiovascular diseases, cirrhosis of the liver, diabetes, the formation of cataracts, cerebral ischaemia, cranial traumas, respiratory distress syndrome (ARDS), cancers and the aging process.

44. A pharmaceutical composition comprising one or more replication defective recombinant adenoviruses according to claim 27.

45. A pharmaceutical composition according to claim 44, in injectable form.

46. A pharmaceutical composition according to claim 44, comprising between 10^4 and 10^{14} pfu/ml of defective recombinant adenoviruses.

47. A pharmaceutical composition according to claim 46, comprising between 10^6 to 10^{10} pfu/ml of defective recombinant adenoviruses.

48. A mammalian cell infected with one or more defective recombinant adenoviruses according to claim 27.

49. A mammalian cell according to claim 48, wherein said cell is a human cell.

50. A mammalian cell according to claim 49, wherein said cell is a retinal cell, fibroblast, myoblast, hepatocyte, endothelial cell, glial cell or keratinocyte.

51. An implant comprising a cell according to claim 48 and an extracellular matrix.

52. An implant according to claim 51, wherein the extracellular matrix comprises a gelling compound.

53. An implant according to claim 52, wherein the gelling compound is selected from the group consisting of collagen, gelatin, glucosaminoglycans, fibronectin, agarose and lectins.

54. An implant according to claim 51, wherein the extracellular matrix comprises a support for anchorage of infected cells.

55. An implant according to claim 54, wherein the support comprises polytetrafluoroethylene fibres.

REMARKS

Claims 1-26 have been cancelled and rewritten as new claims 27-55, in order to conform with US patent practice. Support for the new claims is found in the claims as originally filed. No new matter has been added.

Rhône-Poulenc Rorer Inc.
Legal-Patents #3C43
P.O. Box 5093
Collegeville, PA 19426-0997
Telephone: (610) 454-3816
Facsimile: (610) 454-3808

Dated: *Feb. 11, 1997*

Respectfully submitted,



Martin F. Savitzky
Attorney for Applicants
Registration No. 29,699

ADENOVIRUS COMPRISING A GENE CODING FOR
GLUTATHIONE PEROXIDASE

The present invention relates to recombinant adenoviruses comprising a DNA sequence encoding glutathione peroxidase and its uses in gene therapy.

Glutathione peroxidase is one of the enzymes which are actively involved in the regulation of the concentration of oxygen-derived free radicals formed during various physiological or pathological processes.

Normally, the formation of these radicals, which are highly reactive, such as the superoxide anion, hydrogen peroxide and the hydroxyl radical is controlled as follows: superoxide anion is rapidly converted to hydrogen peroxide, by means of superoxide dismutase, then this hydrogen peroxide is converted to oxygen and water, by catalase or in particular glutathione peroxidase.

Usually, these enzymes are present in practically all tissues.

However, under certain conditions, these regulatory mechanisms are not totally efficient. In particular, there may be a disequilibrium between their respective concentrations, for example an excessive superoxide dismutase concentration compared with the available quantity of glutathione peroxidase, leading to a pathological production of hydrogen peroxide and of free radicals (hydroxyl radicals in particular).

These free radicals may directly induce a

2674920 98/03/2000

peroxidation of membrane lipids, inactivate enzymes by peroxidizing their sulphhydryl groups, depolymerize polysaccharides and/or damage nucleic acids, causing in all cases serious pathologies. They may thus be responsible for inflammations, emphysemas, neoplasms and/or retinopathies. They also appear to be involved in atherosclerosis, cerebral ischaemia, cranial traumas, respiratory distress syndrome, cardiovascular diseases, diabetes, cirrhosis of the liver and formation of cataracts as well as in the aging process. Free radicals are also thought to be linked to the apoptosis process and could be involved in the cell death accompanying the acquired immunodeficiency syndrome (AIDS), [The J. of Biol. Chem., 269, 2(14), 798-801, (1994)]. More recently, it has been demonstrated that reactions between these radicals or with neurotransmitters led to the formation of endogenous neurotoxins. Free radicals are therefore also involved in neurological pathologies such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and/or trisomy 21.

Consequently, it would be particularly valuable to have available nowadays medicinal products which can increase or regulate the glutathione peroxidase concentration in the body and which are therefore effective for treating all the abovementioned pathologies.

The present invention is precisely consists

in the development of vectors which are particularly efficient for delivering in vivo and in a localized manner, therapeutically active quantities of the specific gene encoding glutathione peroxidase or one of its derivatives.

In the corresponding application no. PCT/EP93/02519, it has been shown that adenoviruses could be used as vector for the transfer of a foreign gene in vivo into the nervous system and the expression of the corresponding protein.

The present invention relates more particularly to new constructs which are particularly suitable and efficient for controlling the expression of glutathione peroxidase.

More precisely, it relates to a recombinant adenovirus comprising a DNA sequence for controlling the expression of a glutathione peroxidase, its use for therapeutic treatments and/or the prevention of various pathologies.

The Applicant has thus demonstrated that it is possible to construct recombinant adenoviruses containing a sequence encoding a glutathione peroxidase, to administer these recombinant adenoviruses in vivo, and that this administration allows a stable and localized expression of therapeutically active quantities of glutathione peroxidase in vivo.

A first subject of the invention therefore

consists in a defective recombinant adenovirus comprising at least one DNA sequence encoding all or an active part of a glutathione peroxidase or one of its derivatives.

5 For the purposes of the present invention, glutathione peroxidase designates any enzyme having glutathione peroxidase activity. By way of illustration of these enzymes, there may in particular be mentioned in man the glutathione peroxidases GPX1, GPX2, GPX3 and
10 GPX4. GPX1 and GPX4 are expressed in most tissues with a clear predominance in the erythrocytes, the liver and the kidneys for GPX1 (Chambers et al; EMBO J 5: 1221-1227 (1986)) and in the testicles for GPX4 [Roveri et al; J. Biol. Chem. 267:6142-6146 (1992)]. GPX3 is
15 produced in the kidneys, the lungs, the heart, the breast, the placenta as well as in the liver (Chu et al. Blood 79: 3233_3238 (1992)) as for GPX2, it has mainly been demonstrated in the gastrointestinal tissues and in the liver [Chu et al. J. Biol. Chem.
20 268: 2571-257 (1993)].

The glutathione peroxidase produced within the framework of the present invention may be a human or animal glutathione peroxidase. It may in particular be bovine glutathione peroxidase.

25 The DNA sequence encoding glutathione peroxidase, which is used within the framework of the present invention may be a cDNA, a genomic DNA (gDNA), or a hybrid construct consisting for example of a cDNA

into which one or more introns would be inserted. The nucleic sequence of the cDNA encoding human glutathione peroxidase has been described by [Mullenbach et al., Oxy-Radicals in Molecular Biology and Pathology, 313-
5 326, (1988)]. It may also be synthetic or semisynthetic sequences.

In a particularly advantageous manner, a cDNA or a gDNA is used.

According to a preferred embodiment of the
10 invention, it is a genomic DNA (gDNA) sequence encoding a glutathione peroxidase. Its use may allow an enhanced expression in human cells.

Of course, prior to its incorporation into an adenovirus vector according to the invention, the DNA
15 sequence may be advantageously modified, for example by site-directed mutagenesis, in particular for the insertion of appropriate restriction sites. The sequences described in the prior art are indeed not constructed for a use according to the invention, and
20 prior adaptations may prove necessary in order to obtain high expression levels.

For the purposes of the present invention, derivative is understood to mean any sequence obtained by modification and encoding a product which preserves
25 at least one of the biological properties of glutathione peroxidase. Modification should be understood to mean any mutation, substitution, deletion, addition or modification of a genetic and/or

chemical nature. These modifications can be performed by techniques known to persons skilled in the art (see general molecular biology techniques below). The derivatives according to the invention can also be
5 obtained by hybridization from nucleic acid libraries, using as probe the glutathione peroxidase native sequence or a fragment thereof.

These derivatives are especially molecules having a higher affinity for their binding sites,
10 sequences allowing an enhanced expression in vivo, molecules having a greater resistance to proteases, molecules having a higher therapeutic efficacy or fewer side effects, or possibly new biological properties.

Among the preferred derivatives, there may be
15 mentioned more particularly natural variants, molecules in which one or more residues have been substituted, derivatives obtained by deletion of regions having little or no involvement in the interaction with the binding sites considered or expressing an undesirable
20 activity, and derivatives containing additional residues compared with the native sequence, such as for example a secretory signal and/or a joining peptide.

The DNA sequence, encoding all or part of a glutathione peroxidase or one of its derivatives, may
25 also be an antisense sequence whose expression in the target cell makes it possible to control the expression of this enzyme. Preferably, the heterologous DNA sequence contains a gene encoding an antisense RNA

capable of controlling the translation of the
corresponding mRNA. The antisense sequence may be all
or only part of the DNA sequence encoding a glutathione
peroxidase, inserted in the reverse orientation in the
5 vector according to the invention.

According to one embodiment of the invention,
the DNA sequence encoding a glutathione peroxidase or
one of its derivatives can also integrate a secretory
signal which makes it possible to direct the
10 synthesized glutathione peroxidase in the secretory
pathways of the infected cells. In this manner, the
synthesized glutathione peroxidase is advantageously
released into the extracellular compartments.

Advantageously, the glutathione peroxidase
15 encoding sequence is placed under the control of
signals allowing its expression in the target cells.
Preferably, these are heterologous expression signals,
that is to say signals which are different from those
naturally responsible for the expression of glutathione
20 peroxidase. They may be in particular sequences
responsible for the expression of other proteins, or of
synthetic sequences. In particular, they may be
promoter sequences of eukaryotic or viral genes. For
example, they may be promoter sequences derived from
25 the genome of the cell which it is desired to infect.
Likewise, they may be promoter sequences derived from
the genome of a virus, including the adenovirus used.
In that respect, there may be mentioned for example the

E1A, MLP, CMV, RSV-LTR promoters and the like. In addition, these expression sequences can be modified by addition of activation or regulatory sequences or of sequences allowing a tissue-specific expression. It may
5 be particularly advantageous to use expression signals which are specifically or predominantly active in the target cells, so that the DNA sequence is expressed or produces its effect only when the virus has indeed infected a target cell.

10 In a first specific embodiment, the invention relates to a defective recombinant adenovirus comprising a cDNA or DNA8 sequence encoding a bovine glutathione peroxidase under the control of the RSV-LTR promoter.

15 In another specific embodiment, the invention relates to a defective recombinant adenovirus comprising a gDNA sequence encoding human glutathione peroxidase under the control of the RSV-LTR promoter.

A particularly preferred embodiment of the
20 present invention consists in a defective recombinant adenovirus comprising the ITR sequences, a sequence allowing encapsidation, a DNA sequence encoding human glutathione peroxidase or a derivative thereof under the control of a promoter allowing predominant
25 expression in the target tissues and in which the E1 gene and at least one of the E2, E4, L1-L5 genes is not functional.

The defective adenoviruses according to the

invention are adenoviruses which are incapable of autonomously replicating in the target cell. Generally, the genome of the defective adenoviruses used within the framework of the present invention therefore lacks at least the sequences necessary for the replication of the said virus in the infected cell. These regions can be either removed (completely or partially), or rendered nonfunctional, or substituted with other sequences and especially with the glutathione peroxidase encoding DNA sequence.

Preferably, the defective virus of the invention conserves the sequences of its genome which are necessary for the encapsidation of the viral particles. Still more preferably, as indicated above, the genome of the defective recombinant virus according to the invention comprises ITR sequences, a sequence allowing encapsidation, the nonfunctional E1 gene and at least one of the nonfunctional E2, E4, L1-L5 genes.

There are various serotypes of adenoviruses, whose structure and properties vary somewhat. Among these serotypes, the use of type 2 or 5 human adenoviruses (Ad 2 or Ad 5) or of adenoviruses of animal origin (see Application FR 93 05954) is preferred within the framework of the present invention. Among the adenoviruses of animal origin which can be used within the framework of the present invention, there may be mentioned adenoviruses of canine, bovine, murine [example: MAV1, Beard et al.,

Virology 75 (1990) 81], ovine, porcine, avian or even simian (example: SAV) origin. Preferably, the adenovirus of animal origin is a canine adenovirus, more particularly a CAV2 adenovirus [Manhattan strain or A26/61 (ATCC VR-800) for example]. Preferably, adenoviruses of human or canine or mixed origin are used within the framework of the invention.

The defective recombinant adenoviruses according to the invention can be prepared by any technique known to persons skilled in the art (Levrero et al., Gene 101 (1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917). In particular, they can be prepared by homologous recombination between an adenovirus and a plasmid carrying, inter alia, the glutathione peroxidase encoding DNA sequence. The homologous recombination occurs after co-transfection of the said adenoviruses and plasmid into an appropriate cell line. The cell line used should preferably (i) be transformable by the said elements and (ii) contain the sequences capable of complementing the defective adenovirus genome part, preferably in integrated form in order to avoid risks of recombination. As an example of a cell line, there may be mentioned the human embryonic kidney line 293 (Graham et al., J. Gen. Virol. 36 (1977) 59) which contains especially, integrated into its genome, the left-hand part of the genome of an Ad5 adenovirus (12%). Strategies for constructing vectors derived from adenoviruses have

also been described in Applications Nos. FR 93 05954 and FR 93 08596 which are incorporated into the present application by reference.

Next, the adenoviruses which have multiplied
5 are recovered and purified according to conventional molecular biology techniques as illustrated in the examples.

The particularly advantageous properties of the vectors of the invention stem especially from the
10 construct used (defective adenovirus, deleted of certain viral regions), the promoter used for the expression of the glutathione peroxidase encoding sequence (viral or tissue-specific promoters preferably), and methods for administering the said
15 vector, allowing efficient expression of the said enzyme in the appropriate tissues.

The present invention also relates to any use of an adenovirus as described above for the preparation of a pharmaceutical composition intended for the
20 treatment and/or prevention of the abovementioned pathologies. More particularly it relates to any use of these adenoviruses for the preparation of a pharmaceutical composition intended for the treatment and/or prevention of neurodegenerative diseases such as
25 for example Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and trisomy 21. They can also be advantageously used in the treatment of atherosclerosis, cardiovascular diseases, cirrhosis

of the liver, diabetes, formation of cataracts, cerebral ischaemia, cranial traumas, respiratory distress syndrome (ARDS), diseases linked to an immune deficiency, cancers as well as in the aging process.

5 The present invention also relates to a pharmaceutical composition comprising one or more defective recombinant adenoviruses as described above. These pharmaceutical compositions may be formulated for topical, oral, parenteral, intranasal, intravenous, 10 intramuscular, subcutaneous, intraocular or transdermal administration and the like. Preferably, the pharmaceutical compositions of the invention contain a pharmaceutically acceptable vehicle for an injectable formulation, especially for a direct injection into the 15 patient. These may be in particular isotonic sterile solutions, or dry, especially freeze-dried, compositions which, upon addition, depending on the case, of sterilized water or physiological saline, allow the preparation of injectable solutions.

20 In this respect, the invention also relates to a method for treating neurodegenerative diseases comprising the administration, to a patient, of a recombinant adenovirus as defined above. More particularly, the invention relates to a method for 25 treating neurodegenerative diseases comprising the stereotaxic administration of a recombinant adenovirus as defined above.

The doses of defective recombinant adenovirus

used for the injection can be adjusted according to various parameters, and especially according to the mode of administration used, the relevant pathology or even the desired duration of treatment. Generally, the recombinant adenoviruses according to the invention are formulated and administered in the form of doses of between 10^4 and 10^{14} pfu/ml, and preferably 10^6 to 10^{10} pfu/ml. The term pfu (plaque forming unit) corresponds to the infectivity of a virus solution, and is determined by infecting an appropriate cell culture and measuring, generally after 48 hours, the number of plaques of infected cells. The techniques for determining the pfu titre of a viral solution are well documented in the literature.

Another subject of the invention relates to any mammalian cell infected by one or more defective recombinant adenoviruses as described above. More particularly the invention relates to any human cell population infected by these adenoviruses. This may be in particular fibroblasts, myoblasts, hepatocytes, keratinocytes, endothelial cells, glial cells and the like.

The cells according to the invention can be obtained from primary cultures. These can be collected by any technique known to persons skilled in the art and then cultured under conditions permitting their proliferation. As regards more particularly fibroblasts, these can be easily obtained from

biopsies, for example according to the technique described by Ham [Methods Cell. Biol. 21a (1980) 255]. These cells can be used directly for infection by adenoviruses, or preserved, for example by freezing, for establishing autologous libraries, for subsequent use. The cells according to the invention can also be secondary cultures which are obtained for example from pre-established libraries.

The cultured cells are then infected with the recombinant adenoviruses, so as to confer on them the capacity to produce glutathione peroxidase. The infection is carried out in vitro according to techniques known to persons skilled in the art. In particular, depending on the type of cells used and the desired copy number of virus per cell, persons skilled in the art can adjust the multiplicity of infection. It is clearly understood that these steps should be carried out under appropriate sterile conditions when the cells are intended for administration in vivo. The recombinant adenovirus doses used for the infection of the cells can be adjusted by persons skilled in the art according to the desired aim. The conditions described above for administration in vivo can be applied to infection in vitro.

Another subject of the invention relates to an implant comprising mammalian cells infected with one or more defective recombinant adenoviruses as described above, and an extracellular matrix. Preferably, the

implants according to the invention comprise 10^5 to 10^{10} cells. More preferably, they comprise 10^6 to 10^8 cells.

More particularly, in the implants of the invention, the extracellular matrix comprises a gelling compound and optionally a support permitting anchorage of the cells.

For the preparation of the implants according to the invention, various types of gelling agents can be used. The gelling agents are used for the inclusion of the cells in a matrix having the constitution of a gel, and to enhance the anchorage of the cells on the support, where appropriate. Various cell adhesion agents can therefore be used as gelling agents, such as especially collagen, gelatin, glucosaminoglycans, fibronectin, lectins, agarose and the like.

As indicated above the compositions according to the invention advantageously comprise a support permitting anchorage of the cells. The term anchorage designates any form of biological and/or chemical and/or physical interaction resulting in the adhesion and/or binding of the cells onto the support. Moreover, the cells can either cover the support used, or penetrate inside this support, or both. The use of a solid, non-toxic and/or biocompatible support is preferred within the framework of the invention. In particular, it is possible to use polytetrafluoroethylene (PTFE) fibres or a support of biological origin.

The implants according to the invention can be implanted at different sites in the body. In particular, the implantation can be carried out in the peritoneal cavity, in the subcutaneous tissue

5 (suprapubic region, iliac or inguinal fossae, and the like), in an organ, a muscle, a tumour, the central nervous system or alternatively under a mucous membrane. The implants according to the invention are particularly advantageous in the sense that they make

10 it possible to control the release of the therapeutic product in the body: this release is first determined by the multiplicity of infection and by the number of implanted cells. Next, the release can be controlled

15 either by the removal of the implant, which permanently stops the treatment, or by the use of regulable expression systems, which make it possible to induce or to repress the expression of the therapeutic genes.

The present invention thus provides viral vectors which can be directly used in gene therapy, and

20 which are particularly suitable and efficient for directing the expression of glutathione peroxidase in vivo. The present invention thus offers a new approach which is particularly advantageous for the treatment and/or prevention of many pathologies such as those

25 mentioned above.

The adenoviral vectors according to the invention have, in addition, major advantages, linked especially to their very high efficiency of infection

of the target cells, which make it possible to achieve infections with small volumes of viral suspension. Furthermore, infection with the adenoviruses of the invention is highly localized at the site of injection, which avoids the risks of diffusion to the neighbouring cerebral structures. This treatment may apply both to man and to any animal such as ovines, bovines, murines, domestic animals (dogs, cats and the like), horses, fish and the like.

It is perfectly possible, in addition, to envisage a simultaneous administration of an adenovirus according to the invention with at least a second adenovirus containing a gene encoding one of the forms of superoxide dismutase or catalase.

The examples and the single figure are presented below as a guide and do not limit the scope of the invention.

FIGURE

Figure 1: representation of the enzymatic activity of the glutathione peroxidase obtained from cells 293 infected with 0 to 500 pfu/recombinant adenovirus cell encoding GPx (AdGPx) or β -galactosidase (Ad β gal).

General molecular biology techniques

The methods conventionally used in molecular biology, such as preparative extractions of plasmid DNA, centrifugation of plasmid DNA in caesium chloride gradient, agarose or acrylamide gel electrophoresis,

purification of DNA fragments by electroelution, phenol
or phenol-chloroform extraction of proteins, ethanol or
isopropanol precipitation of DNA in saline medium,
transformation in *Escherichia coli* and the like, are
5 well known to persons skilled in the art and are widely
described in the literature [Maniatis T. et al.,
"Molecular Cloning, a Laboratory Manual", Cold Spring
Harbor Laboratory, Cold Spring Harbor, N.Y., 1982;
Ausubel F.M. et al. (eds), "Current Protocols in
10 Molecular Biology", John Wiley & Sons, New York, 1987].

The pBR322- and pUC-type plasmids and the
phages of the M13 series are of commercial origin
(Bethesda Research Laboratories).

For the ligations, the DNA fragments can be
15 separated according to their size by agarose or
acrylamide gel electrophoresis, extracted with phenol
or with a phenol/chloroform mixture, precipitated with
ethanol and then incubated in the presence of phage T4
DNA ligase (Biolabs) according to the recommendations
20 of the supplier.

The filling of the protruding 5' ends can be
performed with the Klenow fragment of *E. coli* DNA
polymerase I (Biolabs) according to the specifications
of the supplier. The destruction of the protruding 3'
25 ends is performed in the presence of phage T4 DNA
polymerase (Biolabs) used according to the
recommendations of the manufacturer. The destruction of
the protruding 5' ends is performed by a controlled

treatment with S1 nuclease.

Site-directed mutagenesis in vitro by synthetic oligodeoxynucleotides can be performed according to the method developed by Taylor et al.

- 5 [Nucleic Acids Res. 13 (1985) 8749-8764] using the kit distributed by Amersham.

- The enzymatic amplification of DNA fragments by the so-called PCR technique [Polymerase-catalyzed Chain Reaction, Saiki R.K. et al., Science 230 (1985) 1350-1354; Mullis K.B. and Faloona F.A., Meth. Enzym. 155 (1987) 335-350] can be performed using a DNA thermal cycler (Perkin Elmer Cetus) according to the specifications of the manufacturer.
- 10

- The verification of the nucleotide sequences can be performed by the method developed by Sanger et al. [Proc. Natl. Acad. Sci. USA, 74 (1977) 5463-5467] using the kit distributed by Amersham.
- 15

Examples

- Example 1: Procedure for the construction of the vector pLTRIX-bGPx
- 20

- This vector contains the sequence encoding bovine GPx under the control of the RSV virus LTR, as well as sequences from the adenovirus which allow recombination in vivo. The cDNA used is described in [Mullenbach et al., Oxy-Radicals in Molecular Biology and Pathology, 313-326, (1988)].
- 25

The DNA is inserted into the BamHI site of a plasmid Bluescript. A polyadenylation sequence was introduced

into the XhoI site of this plasmid. The latter is identified by SK-bGPx-PolyA.

The vector pLTRIX-bGPx is obtained by introducing an insert obtained by cleavage of SK-bGPx-PolyA into the
5 EcoRV site of the plasmid pLTRIX.

Example 2: Construction of recombinant adenoviruses containing a sequence encoding bovine glutathione peroxidase.

The vector pLTRIX-bGPx is linearized and
10 cotransfected with a deficient adenoviral vector, into the helper cells (line 293) providing in trans the functions encoded by the adenovirus E1 regions (E1A and E1B).

More precisely, the Ad-bGPx adenovirus was
15 obtained by homologous recombination in vivo between the mutant adenovirus Ad-dl1324 (Thimmappaya et al., Cell 31 (1982) 543) and the vector pLTR IX-bGPx, according to the following procedure: the plasmid pLTR IX-bGPx and the Ad-dl1324 adenovirus, linearized
20 by the enzyme ClaI, were cotransfected into the line 293 in the presence of calcium phosphate, so as to allow the homologous recombination. The recombinant adenoviruses thus generated were selected by plaque purification. After isolation, the recombinant
25 adenovirus DNA was amplified in the cell line 293, thereby giving a culture supernatant containing the unpurified recombinant defective adenovirus having a titre of about 10^{10} pfu/ml.

The viral particles are then purified by gradient centrifugation.

Example 3: Control of the expression in vitro of GPx.

For each test, an extract (0.5% triton) is
5 produced from 300,000 cells 293 infected with 0 to
500 pfu/recombinant adenovirus cell encoding GPx or
 β -galactosidase. The enzymatic activity of glutathione
peroxidase is evaluated according to the procedure of
Flohé and Günzler (1984, Methods in Enzymology, Vol;
10 105, pp 114-121). The oxidized glutathione (GSSG)
formed during the GPx reaction is constantly reduced by
an excess of glutathione reductase activity for a
constant level of reduced glutathione (GSH). The
simultaneous oxidation of NADPH is monitored by
15 spectrophotometry.

Figure 1 presents the results obtained.

CLAIMS

1. Defective recombinant adenovirus comprising at least one DNA sequence encoding all or an active part of a glutathione peroxidase or one of its derivatives.
2. Adenovirus according to claim 1, characterized in that the DNA sequence is a cDNA sequence.
3. Adenovirus according to claim 1, characterized in that the DNA sequence is a gDNA sequence.
4. Adenovirus according to claim 1, 2 or 3, characterized in that the DNA sequence encodes a bovine glutathione peroxidase.
5. Adenovirus according to claim 1, 2 or 3, characterized in that the DNA sequence encodes a human glutathione peroxidase.
6. Adenovirus according to claim 1, characterized in that the DNA sequence is an antisense sequence whose expression makes it possible to control the expression of the gene encoding glutathione peroxidase.
7. Adenovirus according to claim 6, characterized in that it is a gene encoding an antisense RNA capable of controlling the translation of the mRNA for a glutathione peroxidase.
8. Adenovirus according to one of claims 1 to 7, characterized in that the DNA sequence is placed

under the control of signals allowing its expression in the target cells.

9. Adenovirus according to claim 8, characterized in that the expression signals are chosen from viral promoters, preferably from the E1A, MLP, CMV and RSV-LTR promoters.

10. Adenovirus according to claim 1, comprising a gDNA or cDNA sequence encoding a bovine glutathione peroxidase under the control of an RSV-LTR promoter.

11. Adenovirus according to claim 1, comprising a gDNA or cDNA sequence encoding a human glutathione peroxidase under the control of an RSV-LTR promoter.

12. Adenovirus according to one of claims 1 to 11, characterized in that it lacks the regions of its genome which are necessary for its replication in the target cell.

13. Adenovirus according to claim 12, characterized in that it comprises ITRs and a sequence allowing encapsidation, and in which the E1 gene and at least one of the E2, E4, L1-L5 genes are not functional.

14. Adenovirus according to claim 12 or 13, characterized in that it is an Ad 2 or Ad 5 type human adenovirus or a CAV-2 type canine adenovirus.

15. Use of an adenovirus according to one of claims 1 to 14, for the preparation of a pharmaceutical

composition intended for the treatment and/or prevention of neurodegenerative diseases.

16. Use according to claim 15, for the preparation of a pharmaceutical composition intended for the treatment and/or prevention of Parkinson's disease, Alzheimer's disease, Huntington's disease, ALS, trisomy 21, atherosclerosis, cardiovascular diseases, cirrhosis of the liver, diabetes, the formation of cataracts, cerebral ischaemia, cranial traumas, respiratory distress syndrome (ARDS), cancers as well as the aging process.

17. Pharmaceutical composition comprising one or more defective recombinant adenoviruses according to one of claims 1 to 15.

18. Pharmaceutical composition according to claim 17, characterized in that it is in injectable form.

19. Pharmaceutical composition according to one of claims 17 to 18, characterized in that it comprises between 10^4 and 10^{14} pfu/ml, preferably 10^6 to 10^{10} pfu/ml of defective recombinant adenoviruses.

20. Mammalian cell infected with one or more defective recombinant adenoviruses according to one of claims 1 to 14.

21. Cell according to claim 20, characterized in that it is a human cell.

22. Cell according to claim 21, characterized in that it is a human cell of the

retinal, fibroblast, myoblast, hepatocyte, endothelial cell, glial cell or keratinocyte type.

23. Implant comprising infected cells according to claims 20 to 22 and an extracellular matrix.

24. Implant according to claim 23, characterized in that the extracellular matrix comprises a gelling compound chosen preferably from collagen, gelatin, glucosaminoglycans, fibronectin, agarose and lectins.

25. Implant according to claims 23 and 24, characterized in that the extracellular matrix also comprises a support allowing anchorage of the infected cells.

26. Implant according to claim 25, characterized in that the support consists preferably of polytetrafluoroethylene fibres.

5

Abstract

The present invention relates to a defective adenovirus
10 comprising at least a DNA sequence coding for all or an active
part of glutathione peroxidase or a derivative thereof. It also
relates to their utilisation in therapy and to the corresponding
pharmaceutical compositions.




Figure 1

[illegible]

ADENOVIRUS COMPRISING A GENE CODING FOR GLUTATHIONE PEROXIDASE

Prior Foreign Applications(s)			Priority Claimed	
FR94/09982	France	12 August 1994	<u>X</u>	<u> </u>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<hr/>			<hr/>	<hr/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)	(Filing Date)	(Status-Patented, Pending or Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I (We) hereby appoint as my (our) attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Martin F. Savitzky	Reg. No. <u>29,699</u>
Paul R. Darkes	Reg. No. <u>33,862</u>
Raymond S. Parker, III	Reg. No. <u>34,893</u>
Ross J. Oehler	Reg. No. <u>33,270</u>

Send Correspondence to:

Martin F. Savitzky
Rhône-Poulenc Rorer Inc.
Legal-Patents, 3C43
P.O. Box 5093
Collegeville, PA 19426-0997

Direct Telephone Calls to:

(610) 454-3816

Martine BARKATS
First or Sole Inventor

French
Citizenship

7, Rue Nicolas-Mouël
Residence Address

Same
Post Office Address

F-75005 Paris
City

Same
City

FRANCE FRX
State (Zip) or Country

Same
State (Zip) or Country

Date

24 March 1997

Signature

Martine Barkats

2-00

Jacques MALLET

Second Inventor

French

Citizenship

18, rue Charcot

Residence Address

Same

Post Office Address

F-75013 Paris

City

Same

City

FRANCE

State (Zip) or Country

Same

State (Zip) or Country

Date

24 march 1987

Signature

Jacques Mallet

3-00

Frédéric REVAH

Third Inventor

French

Citizenship

Bâtiment Flandre 2, 49, rue de Catenay

Residence Address

Same

Post Office Address

F-92160 Antony

City

Same

City

FRANCE

State (Zip) or Country

Same

State (Zip) or Country

Date

4 April 1992

Signature

Frédéric Revah